| 1 |
35044481 | [Relevance of COMT inhibitors in the treatment of motor fluctuations]. | 2022 Jan 19 |
1 |
| 2 |
35463646 | A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson's Disease. | 2022 |
2 |
| 3 |
35563817 | Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients. | 2022 Apr 30 |
1 |
| 4 |
33136226 | Impact of the catechol-O-methyltransferase Val158Met polymorphism on the pharmacokinetics of L-dopa and its metabolite 3-O-methyldopa in combination with entacapone. | 2021 Jan |
3 |
| 5 |
33840171 | In silico discovery and evaluation of phytochemicals binding mechanism against human catechol-O-methyltransferase as a putative bioenhancer of L-DOPA therapy in Parkinson disease. | 2021 Mar |
2 |
| 6 |
34225162 | The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety. | 2021 Sep |
1 |
| 7 |
31837280 | Biotransformation of Piceatannol, a Dietary Resveratrol Derivative: Promises to Human Health. | 2020 Jan |
3 |
| 8 |
33352833 | Entacapone Treatment Modulates Hippocampal Proteins Related to Synaptic Vehicle Trafficking. | 2020 Dec 18 |
1 |
| 9 |
29614697 | Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review. | 2018 |
1 |
| 10 |
29688484 | Effect of the Catechol-O-Methyltransferase Inhibitors Tolcapone and Entacapone on Fatty Acid Metabolism in HepaRG Cells. | 2018 Aug 1 |
1 |
| 11 |
29696585 | Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson's Disease. | 2018 Jun |
1 |
| 12 |
29697034 | Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase. | 2018 |
1 |
| 13 |
30070707 | Enhancing the Cancer Cell Growth Inhibitory Effects of Table Grape Anthocyanins. | 2018 Sep |
1 |
| 14 |
28100326 | [Feeding difficulty and developmental delay for 8 months and nystagmus for 4 months in an infant]. | 2017 Jan |
1 |
| 15 |
28526448 | The catechol-O-methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells. | 2017 Aug |
1 |
| 16 |
26582803 | Development of an HTRF Assay for the Detection and Characterization of Inhibitors of Catechol-O-Methyltransferase. | 2016 Jun |
1 |
| 17 |
26844013 | Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug-Induced Liver Injury. | 2016 Jan |
2 |
| 18 |
27074629 | Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry. | 2016 May 26 |
2 |
| 19 |
27089846 | Comparison of the inhibitory effects of tolcapone and entacapone against human UDP-glucuronosyltransferases. | 2016 Jun 15 |
2 |
| 20 |
27456338 | 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of L-DOPA. | 2016 Jul 25 |
1 |
| 21 |
27522262 | Structure related effects of flavonoid aglycones on cell cycle progression of HepG2 cells: Metabolic activation of fisetin and quercetin by catechol-O-methyltransferase (COMT). | 2016 Oct |
1 |
| 22 |
25639262 | Entacapone and prostate cancer risk in patients with Parkinson's disease. | 2015 Apr 15 |
1 |
| 23 |
26295926 | Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability. | 2015 Dec |
2 |
| 24 |
24148818 | Synergistic inhibition of lung cancer cell lines by (-)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-O-methyltransferase. | 2014 Feb |
2 |
| 25 |
24229565 | Entacapone augmentation of antipsychotic treatment in schizophrenic patients with negative symptoms; a double-blind placebo-controlled study. | 2014 Feb |
1 |
| 26 |
24830331 | Entacapone reduces cortical activation in Parkinson's disease with wearing-off: a f-MRI study. | 2014 |
2 |
| 27 |
23265352 | L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease. | 2013 Feb |
1 |
| 28 |
23281915 | Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque. | 2013 Mar |
1 |
| 29 |
23673910 | Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications. | 2013 May-Jun |
2 |
| 30 |
23948989 | Levodopa in the treatment of Parkinson's disease: current status and new developments. | 2013 Jan 1 |
1 |
| 31 |
22123108 | Bioanalytical chromatographic methods for the determination of catechol-O-methyltransferase inhibitors in rodents and human samples: a review. | 2012 Jan 13 |
1 |
| 32 |
22860182 | Characterization of non-nitrocatechol pan and isoform specific catechol-O-methyltransferase inhibitors and substrates. | 2012 Feb 15 |
1 |
| 33 |
21164341 | Erythrocytes catechol-o-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients. | 2011 Jan-Feb |
6 |
| 34 |
21280081 | The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. | 2011 Jan |
8 |
| 35 |
21524266 | Pharmacological treatment of cannabis dependence. | 2011 |
1 |
| 36 |
21999147 | Diverse facets of COMT: from a plausible predictive marker to a potential drug target for schizophrenia. | 2011 Dec |
1 |
| 37 |
19879254 | Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus. | 2010 Jan 14 |
1 |
| 38 |
19909787 | Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa. | 2010 Jan 14 |
2 |
| 39 |
20077469 | The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF. | 2010 Feb 15 |
1 |
| 40 |
20150427 | Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. | 2010 May 14 |
1 |
| 41 |
20464572 | Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients. | 2010 Oct |
1 |
| 42 |
20572781 | Entacapone. | 2010 Aug |
2 |
| 43 |
20582993 | Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. | 2010 Jul |
1 |
| 44 |
20694135 | Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease. | 2010 Jul 27 |
1 |
| 45 |
20856911 | Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo). | 2010 Sep 7 |
2 |
| 46 |
21095464 | Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease. | 2010 |
1 |
| 47 |
18691454 | Entacapone in elderly Parkinsonian patients experiencing levodopa-related wearing-off: a pilot study. | 2009 Feb |
1 |
| 48 |
19589043 | Levodopa/carbidopa/entacapone in Parkinson's disease. | 2009 Jul |
1 |
| 49 |
19657587 | Peripheral COMT inhibition prevents levodopa associated homocysteine increase. | 2009 Oct |
2 |
| 50 |
19936145 | Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference. | 2009 Nov 3 |
4 |